"Genentech’s unique culture encourages collaboration between experimental and computational scientists to drive both forward and reverse translation."
I completed my PhD in at the University of Pennsylvania in 2017 training as an experimental cancer biologist focusing on the mechanisms underlying tumor-stroma interactions. As a postdoctoral fellow at Stanford University, I trained in an environment that allowed me to step away from the bench and focus on translational and computational analyses. This hybrid training enabled me to pursue a career merging experimental and computational approaches to understand cancer biology.
I came to Genentech in 2020 for three main reasons: 1) the collaborative culture that encourages team science, 2) the phenomenal scientists, and 3) real patient impact. Here, I collaborate across departments to understand immune checkpoint inhibitor response and resistance in lung cancers. Our findings translate in the forward direction to inform rational combinations and biomarker selected trials and also in the reverse direction to understand mechanisms of action and identify new targets.
Throughout my career I have benefited from exceptional mentors and hope to continue that tradition. It is incredibly rewarding to learn from trainees and enable them to investigate new areas while they build their own unique skillset and expertise as they transition to independent positions.
Cancer Cell. 40(3):289-300.
My research focus is primarily on non-small cell lung cancer and small cell lung cancer. While immune checkpoint inhibitors have transformed care for many lung cancer patients much is left to be understood about response and resistance. We utilize advanced analytics of multi-omic profiles of patient tumors in the context of large randomized clinical trials to understand the molecular features and tumor subtypes that drive response or resistance to immune checkpoint inhibition.